CymaBay Therapeutics Inc. (NASDAQ:CBAY) Director Kurt Von Emster sold 211,124 shares of the business’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

CymaBay Therapeutics Inc. (CBAY) opened at 7.67 on Wednesday. The stock’s market cap is $335.61 million. CymaBay Therapeutics Inc. has a 52 week low of $1.15 and a 52 week high of $8.45. The company has a 50-day moving average price of $6.85 and a 200-day moving average price of $5.44.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.06). Equities research analysts anticipate that CymaBay Therapeutics Inc. will post ($0.82) EPS for the current year.

WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/04/kurt-von-emster-sells-211124-shares-of-cymabay-therapeutics-inc-cbay-stock.html.

A number of research firms have commented on CBAY. Oppenheimer Holdings, Inc. began coverage on CymaBay Therapeutics in a research note on Friday, June 23rd. They issued an “outperform” rating and a $8.00 price target for the company. Cantor Fitzgerald started coverage on CymaBay Therapeutics in a report on Tuesday, September 19th. They issued an “overweight” rating and a $16.00 price target for the company. Zacks Investment Research upgraded CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Ifs Securities lowered CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 11th. Finally, SunTrust Banks, Inc. assumed coverage on shares of CymaBay Therapeutics in a report on Friday, August 18th. They set a “buy” rating and a $15.00 price objective on the stock. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $12.69.

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp boosted its holdings in shares of CymaBay Therapeutics by 0.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 140 shares in the last quarter. ClariVest Asset Management LLC purchased a new position in shares of CymaBay Therapeutics in the 1st quarter valued at $105,000. LVM Capital Management Ltd. MI grew its position in shares of CymaBay Therapeutics by 100.0% in the 2nd quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 10,000 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in shares of CymaBay Therapeutics in the 2nd quarter valued at $242,000. Finally, Ardsley Advisory Partners grew its position in shares of CymaBay Therapeutics by 66.2% in the 2nd quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 25.91% of the company’s stock.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.